Knowledge of the cellular distribution and subcellular localization of mannose-terminal glucocerebrosidase after intravenous infusion is necessary for understanding the efficacy of targeted enzyme replacement therapy for Gaucher's disease. Selective uptake of m a n n a s e -t e d gluoxerebrosidase by Kupffer cells in rat liver has been previously demonstrated biochemically. In this study we used immunohistochemical and immunogold labeling techniques to provide direct visual proof for the localization of the delivered enzyme. Light microscopy codirmed biochemical data identlfying non-parenchymal cells as the primary target of the modified glucocerebrosidase. Ushg a primary antibody specific for glucocerebrosidase and a secondary gold-conjugated antibody, we used immunoelectron microscopy to quantify the extent and distribution of exogenous enzyme in various cell types in rat liver and its localization within their respective subcellular organelles. Thirty minutes after intravenous administration of mannose-terminal glucocerebrosidase, enzyme was localized primarily in lysosomes of Kupffer cells. Of eight intact Kupffer cells counted, 16 of 21 lysosomes (78%) contained immunogold conjugates (average concentration 293 gold particles/m*). Of 589 par-Cyfochem 43949-158, 1995) KEY WORDS: Enzyme replacement therapy; Gaucher's disease; Lysosomes; Electron microscopy; Immunogold labeling. 149 25. Willemsen R, vanDongen JM, Ginns EI, Sips HJ, Schram AW, Tager JM, Barranger JA, Reuser AJJ. Ultrastructural localization of glucocerebrosidase in cultured Gaucher's disease fibroblasts by immunocytochemistry.
Introduction
Gaucher's disease is an inborn lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase (glucosylceramidase; P-D-glucosyl-N-acyl-sphingosine glucohydrolase; E.C. 3.2.1.45) and resultant accumulation of glucocerebroside in lysosomes of resident macrophages (1,2). This macrophage storage disorder produces a multisystem disease characterized by progressive visceral enlargement and gradual replacement of the bone marrow with lipid-laden macrophages (reviewed in 3,4). After identification of the enzyme defect in this disorder and recognition of the specific cellular dis-Supported in part by a grant from the National Gaucher Founda-Correspondence to: Dr. Gary J. Murray, Bldg. 10 ticles counted in these lysosomes, 485 (82%) were localized within the lumen of the lysosome; only 104 (18Yo) were membrane-associated. Five of the 21 lysosomes counted were negative for gold. No gold particles were found in the mitochondria of Kupffer cells and very few particles (8.2/pm2) were found over the nucleus. The density of gold particles was also low over the nucleus (7.2/pm2), mitochondria ( 8 . 8 / p 2 ) , and lysosomes ( 7 . 9 / p 2 ) of hepatocytes. No specific labeling was observed in erythrocytes, platelets, lymphocytes, pit cells, fat-storing cells, or bile duct. Background labeling of control liver sections from rats receiving saline injection was 8. 2 1.4 gold partides/p*. We condude that mannose-terminal glucocerebrosidase is delivered to the lysosomes of Kupffer cells in liver and that it is distributed both within the lumen (82%) and over the membrane (18%) of the lysosome, with a slight preferential association with the membrane. These findings may provide insights into the design of more effective therapeutic enzyme preparations for the treatment of Gaucher's disease. (J Hisrochem tribution of stored lipids, administration of exogenous enzyme, possibly targeted to the Kupffer cells, was suggested as a potential therapy for Gaucher's disease ( 5 ) . Initial clinical trials of enzyme replacement therapy with native placental glucocerebrosidase demonstrated reduction in hepatic and plasma glucocerebroside levels. However, the effect of glucocerebrosidase prepared on a large scale by hydrophobic affinity chromatography (6) was inconsistent, apparently because the enzyme was taken up primarily by hepatocytes (3).
The description of a'number of sugar-specific endocytic receptors on various liver cells (reviewed in 7.8) and the identification of the storage cells in Gaucher's disease as reticuloendothelial cells (9) led to the current strategy of targeting enzyme specifically to the site of glycolipid storage within the lysosomes of macrophages. Sequential enzymatic removal of sugar residues from the native enzyme produces mannose-terminal glucocerebrosidase (10,l I), which results in a 57-fold increase in the uptake of glucocerebrosidase in rat liver Kupffer cells compared with uptake of the native glucocerebrosidase (11) . The modified enzyme has been shown by competitive binding and internalization studies to bind to mannosespecific lectins on the surface of macrophages of spleen and liver.
Mannose-terminal glucocerebrosidase has been the subject of a number of clinical trials and has been shown to be highly effective in reversing the clinical manifestations of Gaucher's disease. This macrophage-targeted preparation increases hemoglobin and platelet counts, decreases serum acid phosphatase, and leads to significant reduction of liver and spleen size and skeletal improvement in patients with the disorder (12) (13) (14) (15) . However, one drawback of this treatment has been the initial high dose of enzyme required for effective therapy (16J7).
After administration of mannose-terminal glucocerebrosidase to rats, the enzyme is rapidly internalized and then inactivated (manuscript in preparation). Biochemical measurements have previously been used to elucidate the specificity for Kupffer cells and, more specifically, for the lysosomes within these cells. We undertook the current studies to determine the localization of mannoseterminal glucocerebrosidase at the suborganelle level within the lysosomes of Kupffer cells. By immunogold labeling of eponembedded sections (18) , we present direct visual evidence for the distribution of a significant proportion (80%) of the administered mannose-terminal glucocerebrosidase within the lumen of the lysosome, with a smaller fraction associated with the lysosomal membrane. We suggest that inappropriate membrane localization rather than inappropriate dose ( 1 5~6 ) or nonspecific cell targeting (19) contributes significantly to the low efficiency of current enzyme therapy protocols.
Materials and Methods

Light Microscopy
Tissue Preparation. Normal Sprague-Dawley male rats (200-250 g) from Taconic Laboratories (Germantown, NY) were anesthetized and given a bolus injection of 30 IUlkg of mannose-terminal glucocerebrosidase (Ceredase; Genzyme, Cambridge, MA) into the femoral vein. For immunohistological staining, 1 x 0.5-un pieces of liver were quickly embedded in M1 embedding medium (Lipshaw; Detroit, MI) and quick-frozen in dry ice. Sections (100 pm) were cut on a Cryo-cut I1 Microtome (American Optical).
Immunohistological Staining. Thin sections on glass microscope slides were fixed at 4°C for 2 min with a methanokacetone mixture (U). Polyclonal rabbit serum raised against purified native placental glucocerebrosidase was diluted 1:20 for use in phosphate buffer (PB; 67 mM potassium phosphate, 150 mM NaCI, pH 7.4). After incubation with primary antiserum or control rabbit serum, the glass slides were blocked with 0.1% BSA in PB. Slides were next incubated successively with bridge antibody (donkey anti-rabbit IgG) and then with secondary antibody contained in a peroxidase-anti-peroxidase (PAP) kit (Amersham; Arlington Heights, IL). Final development was carried out at 37% with 0.1% diaminobenzidine and 3% H202 in 10 mM Tris, pH 7.2. Slides were counterstained with Harris modified hematoxylin (Fisher Diagnostics; Orangeburg, NY). Controls were either incubated with normal rabbit serum at the same dilution or the primary antibody was omitted
Electron Microscopy
Immunogold Staining. Fixation and preparation of tissues for immunogold staining were performed essentially as described (20) . Thirty min after IV administration of mannose-terminal glucocerebrosidase. tissues were fixed in situ by cardiac puncture and rapid flushing through the aorta with 0.1 M sodium cacodylate containing 50% sucrose, pH 7.4, followed by perfusion for 20 min with 1% glutaraldehyde in the same buffer. For fixation, an initial flow rate of 15-25 ml/min was used, followed by a flow rate of 5-10 mllmin for 20 min. The liver was then removed and small pieces were fixed en bloc for an additional 2 hr at room temperature (RT) in the same buffer. Tissue blocks were gradually dehydrated by increasing ethanol concentrations and embedded in epon (Epon 812 kit; Electron Microscopy Sciences, Fort Washington, PA). Post-fixation in os04 was omitted in samples for immunogold staining. Thin sections were cut on an LKEi ultramicrotome and placed on formvar-coated nickel grids (Electron Microscopy Sciences).
To etch the plastic surface and expose epitopes for immunological reaction, the grids were floated, section side down, for 1 hr on drops of saturated sodium metaperiodate. After etching the grids were blocked with 0.5 M glycine for 30 min, then washed with 1% BSA in PB for 30 min. Incubation with primary antibody (polyclonal rabbit antiserum against human placental glucocerebrosidase, diluted 1:20) was carried out at RT for 2 hr, after which the grids were washed for 60 min with 1% BSA in PB. Grids were next incubated for 30 min with secondary antibody [goat antirabbit F(ab)2 antiserum conjugated with 10-nm gold particles diluted 1:40 (Ted Pella; Redding, CA)]. Grids were rinsed with PB after each step and finally in distilled water before drying and staining with uranyl acetate and lead citrate. Controls were processed similarly either by omission of primary antibody or substitution with normal rabbit serum at the same dilution. Sections were viewed by electron microscopy on a JEOL 100-CX at 80 kV. Distribution of gold particles was calculated on the basis of area measurements determined from micrographs using Image 1.44 software and a Macintosh-I1 workstation.
Results
Light microscopy of indirect PAP-stained liver sections from rats after administration of mannose-terminal glucocerebrosidase revealed a characteristic yellow-brown color in sinusoidal cells (Figure 1 ). This contrasted with the absence of color in hepatocytes and in any cells from control liver. The distribution of color, primarily over sinusoidal cells, confirms previous biochemical measurements of enzyme activity in isolated liver cell populations after IV administration of mannose-terminal glucocerebrosidase (10,ll) .
Electron microscopic visualization of immunogold-labeled enzyme molecules was used to improve the resolution at the subcellular level. Preliminary experiments using fresh tissue biopsy specimens, fixed en bloc with 1% glutaraldehyde and embedded in epon, resulted in relatively poor preservation of membrane structures in hepatocytes and other cell types. Others have reported similar results (20) , including the observation that in the absence of osmification, glycogen deposits were leached from the hepatocytes, leaving clear areas in the cytoplasm. If Os04 were used before epon embedding, much better ultrastructure would be observed. However, this would also interfere with the gold labeling. To improve preservation while still permitting immunogold labeling, perfusion of rat liver in situ with 1% glutaraldehyde as described (20) was used. In well-perfused liver preparations, structures may be preserved in the absence of post-fixation with 0~0 4 . Post-embedding immunocytochemistry was performed with polyclonal rabbit antiserum against human placental glucocerebrosidase, followed by a secondary goat anti-rabbit F(ab)z antibodygold conjugate. ing endosomes, also contained a small number of gold particles (not shown). Particles were also observed associated with the plasma membrane ( Figures 3A and 3B, arrows) . Howcver. their concentration was no different from that of background. Staining of the sinusoidal lumen also exhibited only background staining.
The observed gold particles over the nucleus of the hepatocyte ( 7 . 2 1~~) were in the range of nonspecific background and were uniform over the entire cell (Figure 4) . The concentration in the lysosomes of endothelial cells (96 f 78 pm2) was considerably higher than background and may indicate specific enzyme uptake into these cells by receptor-mediated endocytosis (Figure 5 ). The high level of error associated with this measurement is due to the small area of several individual lysosomes counted in these cells. These data indicate that endothelial cells do intemalize mannoseterminal glucocerebrosidase to some extent. No specific labeling was observed in erythrocytes, pit cells, fat-storing cells, or bile duct (lible 1).
A detailed examination of a number of Kupffer cells was undertaken to determine the localization of the immunogold particles within the lysosomes ( Table 2) . All Kupffir cells observed in sections obtained from animals receiving mannose-terminal glucocerebmidase contained lysosomal gold. Of eight intact Kupfkr cells counted, 15 of 21 lysosomes (71.4%) contained gold (average gold concentration 293 particles/m2). Five of the 21 lysosomes counted were negative for gold. Examples of both positive and negative lysosomes within the same cell were also observed. Of 589 particles counted in these lysosomes, 485 (82%) were localized over the lysosomal matrix and are presumed to represent enzyme within the lysosomal lumen; only 104 (18%) were membrane-associated. At higher magnification (Figure 3B) , it is clear that the antigen is distributed over the entire lysosome, including both luminal and membrane regions. Finally, although our results clearly demonstrate a significant proportion of the administered enzyme in the region of the lysosomal lumen, we recognize that there remains a preferential association with membrane regions, since 18% of the total gold particles observed in lysosomes were associated with the relatively small area constituting the membrane bilayer compared with the larger area of the lumen. sion of mannose-terminal glucocerebrosidase were developed using normal rabbit serum in place of specific antiserum as the primary antibody. Similar results were obtained for all cell types and for saline-infused control rat liver specimens using the specific primary antiserum (anti-glucocerebrosidase) followed by secondary goldconjugated goat anti-rabbit antiserum. Quantitation was performed only on specimens developed with both primary and secondary antisera. The background gold staining in negative control acpcriments (either saline-infused controls or enzyme infuscd specimens developed only with normal rabbit serum) was 8.2 f 1.4 gold particles/ m2 in all cell types, including Kupffer cells. This is in contrast to the high concentration of gold particles seen in the lysosoma ofKup&r cells from animals that received mannose-terminal
Discussion
Ideally, testing of therapeutic strategies should be performed in a model system that best approximates the disease to be treated. Cell cultures used for study of the uptake and distribution of exogenous enzyme offer advantages in that environment and other variables arc more readily controlled, permitting measurement of q u ilibrium binding constants and number of receptors. However, difficulty in isolating absolutely pure populations of individual cell types for measurement l i m i t s the utility ofthis apptoach. Ultimately, whole-animal studies remain necessary to approximate the hetero-
geneous environment present in patients receiving enzyme therapy. Although a mouse model has been developed for Gaucher's disease, the knock-out model is inappropriate for study of enzyme or other therapy for this disease because the deletion introduced into the gene is lethal in utero or within a few hours of birth (21). By application of immunological detection with light and electron microscopy of tissues obtained from normal rats receiving enzyme, our objective was to demonstrate the association of the administered enzyme with the specific cell types targeted for delivery and to provide unequivocal evidence regarding the precise subcellular localization of the exogenous enzyme within these cell types. Rapid in situ fixation offers the opportunity to observe the instantaneous distribution of an administered protein without concern for artifacts introduced as a result of prolonged cell or organelle isolation procedures. The utility of these methods can be extended to the determination of the subcellular localization of enzyme in model studies of gene replacement therapy, as described by a number of laboratories (22,23).
Glucocerebrosidase, normally a membrane-bound lysosomal enzyme, has been solubilized by detergent extraction ind modified by exoglycosidase digestion to expose core mannose-terminal oligosaccharides. The foundation for enzyme replacement therapy for patients with lysosomal storage disorders is the delivery of highly purified enzymes to the storage organelles. In Gaucher's disease, the lysosomes of reticuloendothelial cells, particularly in the liver, spleen, and bone marrow, are the primary site of glucocerebroside storage and have therefore been the target for the replacement enzyme. Successful targeting of glucocerebrosidase to non-parenchymal cells via the mannose-specific endocytic receptor has been previously documented by biochemical data using cell populations isolated from rat liver (10,ll). However, because these studies were unable to differentiate between macrophages (Kupffer cells) and other non-parenchymal cells, it has been possible to measure delivery of glucocerebrosidase activity only to pooled non-parenchymal cells (1 1). This heterogeneous cell population includes endothelial cells, pit cells, and fat-storing cells in addition to the targeted Kupffer cells (24). Binding and uptake by other cells may significantly reduce the enzyme available for catabolism of stored glycolipid in reticuloendothelial cells. In this study we were able to examine each of these types of cells individually to determine the relative amount of glucocerebrosidase uptake after mannose-specific delivery. With immunogold labeling at the electron microscopic level, a clear picture of enzyme distribution emerges. The increased concentration of gold particles over the lysosomes of Kupffer cells (36-fold higher than background) offers a semiquantitative comparison with the 57-fold increase in enzyme specific activity measurements in isolated nonparenchymal cell populations (10,ll). Our data also indicate for the first time significant uptake of mannose-terminal glucocerebrosidase by endothelial cells of liver. The concentration of gold particles observed in endothelial cells was only one third that seen in Kupffer cells. However, this is more than tenfold higher than that seen in other cell types. Sat0 and Beutler (19) have reported low-affinity mannose-specific binding of mannose-terminal glucocerebrosidase in a variety of cell types and conclude that the broad cell-type specificity of binding observed would lead to considerable losses of administered enzyme at high doses of mannose-terminal glucocerebrosidase. The inappropriate use of graphical analysis of limited data by these authors leaves many questions concerning the validity of their conclusions with respect to both the number and affinity of the receptors reported. Aside from analytical and methodological questions, which are outside the scope of this article and will be addressed fully elsewhere (manuscript in preparation), a number of factors must also be considered in assessing the potential impact of equilibrium-binding measurements on therapeutic strategies. Intracellular ligand concentration may be influenced not only by receptor affinity and number but also by accessibility to the receptor site and, most importantly, by the endocytic rate. The equilibrium constant, a product of both forward and reverse reaction velocities, is far less important than is forward rate of reaction, i.e.. the rate of formation of the receptor-ligand complex, since bound ligand is rapidly and irreversibly removed from the plasma compartment.
Distribution of immunogold over lysosomes of KujHer cells after intravenous infusion of mannose-terminal nlucocerebrosidase in rat
Our results indicate a high degree of selectivity in cell distribution, with a threefold elevation in concentration in Kupffer cells with respect to endothelial cells. These data, collected after in vivo processing of the modified enzyme in normal liver and without the above-mentioned errors of analysis and interpretation, are more likely to reflect the true pharmacodynamics in patients receiving enzyme therapy.
We acknowledge that our own data reported here are limited to a single measurement at a fixed time post infusion and that this time may be an important factor in determining distribution. In selecting a time for observation, we attempted to allow adequate time for internalization and cell fusion but to minimize degrada- tion. With these caveats in mind, we can predict that liver endothelial cells and Kupffer cells are the primary beneficiaries of administered enzyme. Distribution of gold particles over nontargeted cells in animals receiving mannose-terminal glucocerebrosidase was comparable, both in pattern and concentration of grains per unit area, with the nonspecific adsorption of immunogold found in saline infused rats. The presence of normal rat glucocerebrosidase should not alter the observed distribution because (a) rabbit polyclonal anti-glucocerebrosidase does not crossreact with the rat enzyme and (b) the association of native glucocerebrosidase with artificial membranes in vitro occurs in the absence of protein or other factors without any indication of saturation (unpublished observations).
Efficacy of exogenously supplied enzymes has previously been evaluated solely on cell type selectivity. Of equal importance to the ultimate success of enzyme replacement therapy for Gaucher's disease are the subcellular localization of glucocerebrosidase and the distribution of the enzyme within the storage organelle. The association of endogenous glucocerebrosidase with the lysosomal membrane in normal and Type 1 Gaucher fibroblasts has been shown ( 2 5 ) . The present observation of gold particles in Kupffer cells, not only over the lysosomal membrane but also within the lumen of the lysosome, provide new data that address the question of proper intracellular targeting of the exogenous enzyme. The apparently uniform distribution of >80% of the gold particles over the lysosomal lumen indicates that this enzyme has not yet been successfully targeted for the lysosomal membrane and may be responsible for the rapid inactivation observed in rat liver studies (manuscript in preparation), and may provide one explanation for the requirement for high doses of enzyme for effective therapy. If so, one way to improve the effectiveness of exogenous mannoseterminal glucocerebrosidase for treating patients with Gaucher's disease is to improve the subcellular localization within the targeted reticuloendothelial cells, leading to increased efficacy and longer biological lifetime of this therapeutic enzyme. Several factors have now been characterized that activate glucocerebrosidase in vitro and may perform a similar function in vivo. These include anionic lipids such as phosphatidyl serine, fatty acids, and protein activators (26,27). Incorporation of glucocerebrosidase into a vehicle composed of any or all of these factors may result in an improved second-generation drug for enzyme therapy of Gaucher's disease. If it can be accomplished effectively, delivery of glucocerebrosidase not only to the lysosome but to the lysosomal membrane within the lysosome might be expected to increase the effectiveness of treatment by increasing the proximity of hydrolytic activity to the stored substrate, and may also prolong the residence time of active enzyme within the lysosome by protecting it from degradation or inactivation in the lumen.
